HHHiroo Hasegawa

Hiroo Hasegawa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hiroo Hasegawa has a total of 223 co-authors. Here are the top co-authors by number of shared publications:

  • Katsunori Yanagihara

    Department of Laboratory Medicine Nagasaki University Hospital Nagasaki Nagasaki Japan

    13 shared publications
  • Katsunori Yanagihara

    Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

    12 shared publications
  • Daisuke Sasaki

    Department of Laboratory Medicine Nagasaki University Hospital Nagasaki Japan

    9 shared publications
  • Kazuto Tsuruda

    Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

    8 shared publications
  • Norihito Kaku

    Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

    8 shared publications
  • Naoki Uno

    Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

    7 shared publications

Latest Publications

  • PLK1 inhibition enhances Brentuximab vedotin efficacy in CD30-positive T-cell lymphoma via spindle assembly checkpoint activation

    by Yuto Mori, Keito Suto, Norio Takei, Keito Yokoyama, Masahiro Chiba, Takashi Ishio, Hideki Goto, Tomoyuki Endo, Hiroo Hasegawa, Michiyuki Maeda, et al.

    Peripheral T-cell lymphomas (PTCLs) are aggressive malignancies with poor clinical outcomes and limited treatment options. Brentuximab vedotin (BV), a CD30-targeted antibody-drug conjugate, has shown efficacy in CD30-positive PTCLs but is frequently associated with incomplete responses and relapse. To enhance its therapeutic effect, we previously identified defects in spindle assembly checkpoint (SAC) regulation as key sensitizers to BV via a genome-wide CRISPR-Cas9 screen. Building on this, we conducted a cell cycle-focused chemical screen and identified polo-like kinase 1 (PLK1) inhibitors as potent synergistic partners for BV. Among them, volasertib consistently enhanced BV-induced cytotoxicity across multiple CD30-positive PTCL cell lines. Mechanistically, the BV-volasertib combination induced sustained mitotic arrest through activation of the SAC, followed by mitotic catastrophe, apoptosis, and DNA damage. This SAC dependence was further supported by the use of a selective Mps1 inhibitor. Importantly, the combination significantly suppressed tumor growth and prolonged survival in both cell line-derived and patient-derived xenograft (PDX) models. These findings underscore the therapeutic potential of combining BV with PLK1 inhibition, and highlight SAC activation as a key mechanism to overcome therapeutic resistance in CD30-positive PTCL.


  • Open Access

    Rapid Typing of Extended‐Spectrum β‐Lactamase (ESBL)‐ and Metallo‐β‐Lactamase (MBL)‐Producing Enterobacterales Using Fourier Transform Infrared (FT‐IR) Spectroscopy

    by Yasuhide Kawamoto, Kosuke Kosai, Mika Murata, Kenji Ota, Fujiko Mitsumoto‐Kaseida, Norihito Kaku, Hiroo Hasegawa, Koichi Izumikawa, Hiroshi Mukae, Katsunori Yanagihara

    This study investigated the usefulness of the IR Biotyper, which types bacterial strains using Fourier transform infrared (FT‐IR) spectroscopy, against extended‐spectrum β‐lactamase (ESBL)‐ and metallo‐β‐lactamase (MBL)‐producing Enterobacterales. Sixty‐six clinical isolates (20 ESBL‐producing Klebsiella pneumoniae , 15 IMP‐producing K. pneumoniae , and 31 IMP‐producing Enterobacter cloacae complex isolates) were analyzed using the IR Biotyper, pulsed‐field gel electrophoresis (PFGE), multilocus sequence typing (MLST), and whole‐genome single‐nucleotide polymorphism (wgSNP) analyses and the results were compared. Of the 20 ESBL‐producing K. pneumoniae strains analyzed, the IR Biotyper detected three clusters. Of these clusters, two were determined as respective clusters by PFGE and wgSNP analyses, and the strains included in each cluster showed the same STs. The IR Biotyper detected three clusters in the analysis of 15 IMP‐producing K. pneumoniae strains. Of these clusters, strains in the two clusters showed high concordance with PFGE, MLST, and wgSNP analyses. The IR Biotyper identified six clusters among the IMP‐producing E. cloacae complex isolates. These results were fully concordant with those of PFGE, MLST, and wgSNP analyses in the two clusters. The range of adjusted Rand index was 0.734–0.967 between the IR Biotyper and PFGE and 0.658–0.857 between the IR Biotyper and MLST or wgSNP analyses. This study demonstrated the performance of IR Biotyper for the detection of clonal similarities in ESBL‐ and IMP‐producing Enterobacterales and it might be useful for outbreak investigation.

  • Open Access

    Efficacy and Limitations of Flow Cytometry for the Rapid Diagnosis of Primary Central Nervous System Lymphoma

    by Hikaru Nakamura, Takeshi Hiu, Takeharu Kato, Nozomi Ueki, Ayaka Matsuo, Michiharu Yoshida, Shiro Baba, Kenta Ujifuku, Koichi Yoshida, Hirofumi Koike, et al.

    Background/Objectives: Primary central nervous system lymphoma (PCNSL) has a markedly high proliferation rate, making early diagnosis and prompt therapeutic intervention essential. To accelerate diagnosis, our institution adopted flow cytometry (FCM) in conjunction with conventional histopathology, and this study therefore evaluated the diagnostic performance of FCM for PCNSL. Methods: We retrospectively analyzed 67 consecutive patients with suspected PCNSL who underwent intraoperative FCM between 2010 and 2023 based on preoperative imaging. B-cell clonality was defined as ≥20% CD19/CD20-positive cells with a κ/λ ratio of >3.0 or p < 0.01), although these were pathologically diagnosed as diffuse large B-cell lymphoma based on histology and immunohistochemistry. Conclusions: FCM yields reliable diagnostic information within hours of tissue collection and supports early therapeutic decisions in PCNSL. Discordant results may reflect reactive T-cell infiltration. This is the first study to present detailed subset analyses in PCNSL using FCM in correlation with pathology, underscoring its utility as a rapid diagnostic tool.


  • Timing of illness onset influences leukocyte destruction in critically ill patients with suspected sepsis

    by Yoshitomo Morinaga, Motohiro Sekino, Kazuto Tsuruda, Hiroo Hasegawa, Tetsuya Hara, Katsunori Yanagihara

  • Open Access

    Clinical Evaluation of a Rapid Reciprocal-Flow PCR Assay and Real-Time PCR Assay with Quenching Probe for Detection of Mycobacterium tuberculosis Complex

    by Kosuke Kosai, Keisuke Matsumoto, Takahisa Ishikawa, Yasuhide Kawamoto, Norihiko Akamatsu, Kenji Ota, Fujiko Mitsumoto-Kaseida, Norihito Kaku, Hiroo Hasegawa, Koichi Izumikawa, et al.

    This study investigated the diagnostic efficiencies of two assays for the detection of Mycobacterium tuberculosis complex: (1) the reciprocal-flow real-time polymerase chain reaction (PCR)-based GeneSoC assay and (2) the real-time PCR based GENECUBE MTB assay with quenching probe. These assays were performed for stored clinical samples and results were compared with the confirmed results based on culture and COBAS TaqMan MTB assay. A total of 53 samples (20 confirmed positives and 33 confirmed negatives) were included in the performance analysis. The GeneSoC assay showed concordance in all 53 samples, regardless of specimen type, while the GENECUBE MTB assay showed concordance in 19 of the 20 confirmed positive samples and all 33 confirmed negative samples. The overall agreement was 100.0% for the GeneSoC assay and 98.1% for the GENECUBE MTB assay. Positive and negative percent agreements were 100.0% each for the GeneSoC assay and 95.0% and 100.0%, respectively, for the GENECUBE MTB assay. Both the GeneSoC and GENECUBE MTB assays exhibited excellent performance in detecting M. tuberculosis complex. The GeneSoC assay is useful for independent assays of individual samples, whereas the GENECUBE MTB assay is suitable for batch assays of multiple samples.

  • Open Access

    Whole-genome CRISPR screening identifies molecular mechanisms of PD-L1 expression in adult T-cell leukemia/lymphoma

    by Masahiro Chiba, Joji Shimono, Keito Suto, Takashi Ishio, Tomoyuki Endo, Hideki Goto, Hiroo Hasegawa, Michiyuki Maeda, Takanori Teshima, Yibin Yang, et al.

    Adult T-cell leukemia/lymphoma (ATLL) is an aggressive T-cell malignancy with a poor prognosis and limited treatment options. Programmed cell death ligand 1(PD-L1) is recognized to be involved in the pathobiology of ATLL. However, what molecules control PD-L1 expression and whether genetic or pharmacological intervention might modify PD-L1 expression in ATLL cells are still unknown. To comprehend the regulatory mechanisms of PD-L1 expression in ATLL cells, we performed unbiased genome-wide clustered regularly interspaced short palindromic repeat (CRISPR) screening in this work. In ATLL cells, we discovered that the neddylation-associated genes NEDD8, NAE1, UBA3, and CUL3 negatively regulated PD-L1 expression, whereas STAT3 positively did so. We verified, in line with the genetic results, that treatment with the JAK1/2 inhibitor ruxolitinib or the neddylation pathway inhibitor pevonedistat resulted in a decrease in PD-L1 expression in ATLL cells or an increase in it, respectively. It is significant that these results held true regardless of whether ATLL cells had the PD-L1 3' structural variant, a known genetic anomaly that promotes PD-L1 overexpression in certain patients with primary ATLL. Pevonedistat alone showed cytotoxicity for ATLL cells, but compared with each single modality, pevonedistat improved the cytotoxic effects of the anti–PD-L1 monoclonal antibody avelumab and chimeric antigen receptor (CAR) T cells targeting PD-L1 in vitro. As a result, our work provided insight into a portion of the complex regulatory mechanisms governing PD-L1 expression in ATLL cells and demonstrated the in vitro preliminary preclinical efficacy of PD-L1–directed immunotherapies by using pevonedistat to upregulate PD-L1 in ATLL cells.


  • Open Access

    Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas

    by Masahiro Chiba, Joji Shimono, Takashi Ishio, Norio Takei, Kohei Kasahara, Reiki Ogasawara, Takahide Ara, Hideki Goto, Koh Izumiyama, Satoko Otsuguro, et al.

    Adult T-cell leukemia/lymphoma (ATLL) is one of the aggressive peripheral T-cell neoplasms with a poor prognosis. Accumulating evidence demonstrates that escape from adaptive immunity is a hallmark of ATLL pathogenesis. However, the mechanisms by which ATLL cells evade natural killer (NK)-cell–mediated immunity have been poorly understood. Here we show that CD48 expression in ATLL cells determines the sensitivity for NK-cell–mediated cytotoxicity against ATLL cells. We performed unbiased genome-wide clustered regularly interspaced short palindromic repeat (CRISPR) screening using 2 ATLL-derived cell lines and discovered CD48 as one of the best-enriched genes whose knockout conferred resistance to YT1–NK cell line-mediated cytotoxicity. The ability of CD48-knockout ATLL cells to evade NK-cell effector function was confirmed using human primary NK cells with reduced interferon-γ (IFNγ) induction and degranulation. We found that primary ATLL cells had reduced CD48 expression along with disease progression. Furthermore, other subgroups among aggressive peripheral T-cell lymphomas (PTCLs) also expressed lower concentrations of CD48 than normal T cells, suggesting that CD48 is a key molecule in malignant T-cell evasion of NK-cell surveillance. Thus, this study demonstrates that CD48 expression is likely critical for malignant T-cell lymphoma cell regulation of NK-cell–mediated immunity and provides a rationale for future evaluation of CD48 as a molecular biomarker in NK-cell–associated immunotherapies.


  • Open Access

    Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma

    by Takashi Ishio, Sarvesh Kumar, Joji Shimono, Anusara Daenthanasanmak, Sigrid Dubois, Yuquan Lin, Bonita Bryant, Michael N. Petrus, Emmanuel Bachy, Da Wei Huang, et al.

    Adult T-cell leukemia/lymphoma (ATLL) is an aggressive T-cell malignancy with a poor prognosis with current therapy. Here we report genome-wide CRISPR-Cas9 screening of ATLL models, which identified CDK6, CCND2, BATF3, JUNB, STAT3, and IL10RB as genes that are essential for the proliferation and/or survival of ATLL cells. As a single agent, the CDK6 inhibitor palbociclib induced cell cycle arrest and apoptosis in ATLL models with wild-type TP53. ATLL models that had inactivated TP53 genetically were relatively resistant to palbociclib owing to compensatory CDK2 activity, and this resistance could be reversed by APR-246, a small molecule activator of mutant TP53. The CRISPR-Cas9 screen further highlighted the dependence of ATLL cells on mTORC1 signaling. Treatment of ATLL cells with palbociclib in combination with mTORC1 inhibitors was synergistically toxic irrespective of the TP53 status. This work defines CDK6 as a novel therapeutic target for ATLL and supports the clinical evaluation of palbociclib in combination with mTORC1 inhibitors in this recalcitrant malignancy.


  • Rapid detection and surveillance of cfiA-positive Bacteroides fragilis using matrix-assisted laser desorption ionization time-of-flight mass spectrometry

    by Yasuhide Kawamoto, Kosuke Kosai, Kenji Ota, Naoki Uno, Kei Sakamoto, Hiroo Hasegawa, Koichi Izumikawa, Hiroshi Mukae, Katsunori Yanagihara